Drugmakers compete to launch treatments for blood clots

08/30/2010 | New York Times (tiered subscription model), The

Several companies are racing to develop anti-coagulants to replace warfarin for patients with an increased risk of stroke and blood clots. Experimental anti-clotting drugs apixaban and rivaroxaban are thought to have potential in stroke prevention.

View Full Article in:

New York Times (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Paralegal, Legal-Regulatory
Confidential
Piscataway, NJ